Roche shares SMA data ahead of scrap with Biogen, Novartis

Roche has presented more of the data that could enable it to challenge Biogen and Novartis for the spinal muscular atrophy (SMA) market. The readout shows 29% of infants with the most severe form of the disease could briefly sit without support after taking risdiplam, adding to evidence that Roche has a viable challenger for the market.